Antisense oligodeoxynucleotides targeting the serine/threonine kinase Pim-2 inhibited proliferation of DU-145 cells

Acta Pharmacologica Sinica

Volumn 26, Issue 3, 2005, Pages 364-368

  Dai, Jin Ming ^a   Zhang, Shu Qun ^b   Zhang, Wei ^a   Lin, Ru Xian ^a   Ji, Zong Zheng ^b   Wang, Sheng Qi ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b THE SECOND AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Antisense oligodeoxynucleotide; Cell proliferation; DU 145; Pim 2

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; PROTEIN SERINE KINASE;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; PROSTATE CANCER; PROTEIN CONTENT;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; G1 PHASE; HUMANS; MALE; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; TRANSFECTION;

EID: 15244356381     PISSN: 16714083     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2005.00050.x     Document Type: Article

References (20)

1. Gonzalgo ML, Isaacs WB. Molecular pathways to prostate cancer. J Urol 2003; 170: 2444-52.
2. Maitland NJ, Stanbridge LJ, Dussupt V. Targeting gene therapy for prostate cancer. Curr Pharm Des 2004; 10: 531-55.
3. Hernandez I, Maddison LA, Wei Y, DeMayo F, Petras T, Li B, et al. Prostate-specific expression of p53 (R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival. Mol Cancer Res 2003; 1: 1036-47.
4. Pei L, Peng Y, Yang Y, Ling XB, Van Eyndhoven WG, Nguyen KC, et al. PRC17, a novel oncogene encoding a Rab GTPase activating protein, is amplified in prostate cancer. Cancer Res 2002; 62: 5420-54.
5. Mora LB, Buttner R, Seigne J, Diaz J, Ahmad N, Garica R, et al. Constitutive activation of stats in human prostate tumors and cell lines: direct inhibition of Stat3 signalling induces apoptosis of prostate cancer cells. Cancer Res 2002; 62: 6659-66.
6. Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W, et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 1984; 37: 141-50.
7. Eichmann A, Yuan L, Breant C, Alitalo K, Koskinen PJ. Developmental expression of Pim kinases suggests functions also outside of the hematopoietic system. Oncogene 2000; 19: 1215-24.
8. van der Lugt NM, Domen J, Verhoeven E, Linders K, van der Gulden H, Allen J. Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J 1995; 14: 2536-44.
9. Allen JD, Verhoeven E, Domen J, vanderValk M, Berns A. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene 1997; 15: 1133-41.
10. Saris CJ, Domen J, Berns A. The Pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J 1991; 10: 655-64.
11. Yan B, Zemskova, Holder S, Chin V, Kraft A. The PIM-2 kinase phosphorylates BAD on seine 112 and reverses BAD-induced cell death. J Biol Chem 2003; 46: 45358-67.
12. Chalk AM, Sonnhammer EL. Computational antisense oligo prediction with a neural network model. Bioinformatics 2002; 18: 1567-75.
13. Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW. Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997; 57: 4029-35.
14. Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, Magnuson NS. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 2002; 1593: 45-55.
15. Yang SP, Song ST, Tang ZM, Song HF. Optimization of antisense drug design against conservative local motif in simulant secondary structures of HER-2 mRNA and QSAR analysis. Acta Pharmacol Sin 2003; 24: 897-902.
16. Zheng SX, Zhou LJ, Zhu XZ, Jin YX. Antisense oligodeoxynucleotide inhibits vascular endothelial growth factor in human glioma cells. Acta Pharmacol Sin 2000; 21: 211-4.
17. Sun HZ, Wu SF, Tu ZH. Knockdown of IGF-IR by antisense oligodeoxynucleotide auguments the sensitivity of bladder cancer cells to mitomycin. Acta Pharmacol Sin 2001; 22: 841-6.
18. Lahn M, Sundell K, Moore S. Targeting protein kinase C-alpha (PKC-alpha) in cancer with the phosphorothioate antisense oligonucleotide aprinocarsen. Ann NY Acad Sci 2003; 1002: 263-70.
19. Datta SR, Ranger AM, Lin MZ, Sturgill JF, Ma YC, Cowan CW, et al. Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev Cell 2002; 3: 631-43.
20. Plas DR, Thompson CB. Cell metabolism in the regulation of programmed cell death. Trends Endo Met 2002; 13: 74-8.